Weight Loss Clinical Trial
Official title:
A Multi-center, Open-label Study to Evaluate the Synergistic Effects of Biostimulator and Dermal Fillers for Cheek Augmentation and Correction of Contour Deficiencies
Adult subjects with a history of or currently taking glucagon-like peptide-1 (GLP-1) receptor agonist medication and moderate-to-severe cheek wrinkles and midface contour deficiencies will be treated with Sculptra correction of fine lines and wrinkles in the cheek area and Restylane Lyft or Restylane Contour for cheek augmentation and correction of midface contour deficiencies.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | October 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 22 Years to 65 Years |
Eligibility | Inclusion Criteria: - Any Fitzpatrick skin types I-VI, with effort to include minimum n = 1 for each category per site - Any races and ethnicities, with effort to include minimum n = 2 per site for whom identify as American Indian or Alaska Native, Eastern/Southeastern Asian, South Asians, Hispanic or Latino, Black or African American, Native Hawaiian or Other Pacific Islander, etc. - Subject with moderate-to-severe cheek wrinkles on the GCWS - Subject with mild-to-severe midface contour deficiencies on the MMVS - Subject with intent to undergo correction of cheek augmentation or midface contour deficiencies. - Subject with history of taking or currently taking GLP-1 receptor agonist medications such as semaglutide, liraglutide, etc. - Subject with stable Body Mass Index (BMI) within 4-6 weeks before study start. - Subject willing to maintain a stable Body Mass Index (BMI, ± 2 kg/m2) throughout the study. - Willing to maintain the current lifestyle and daily routine (e.g., diet, exercise, sleep, etc.) throughout the study. - Subject willing to be photographed at each visit. - Subject willing to abstain from any other facial plastic surgical or cosmetic procedure(s) during the duration of the study. - For female subjects of childbearing potential, she agrees to use an acceptable form of effective birth control for the duration of the study. Subjects must be willing to take a urine pregnancy test (UPT) prior to all treatments. (Females of non-childbearing potential, e.g., post-menopausal (absence of menstrual bleeding for 1 year without any other medical reason), hysterectomy, or bilateral ovariectomy, are not required to have a UPT.) - Male subjects must be willing to shave prior to each study visit. - Ability to read, understand and give consent for participation in the study. - Agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments. Exclusion Criteria: - Pregnant, breastfeeding, or planning pregnancy during the course of the study. - Current smokers or consumer of nicotine. - History of allergy or hypersensitivity to any ingredient of the treatment products, anesthetics or lidocaine - Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions - Previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except the lips - History of injectable polymethylmethacrylate (PMMA) treatment - Previous treatment/procedure in the face in the previous 6 months that, in the Investigator's opinion, would interfere with the study injections and/or study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures in the treatment area at any time during the study - Presence of any disease or lesions near or on the area to be treated - History of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation (e.g., aspirin or other non-steroidal anti-inflammatory drugs), omega 3, or vitamin E within 14 days before treatment. Omega 3 and vitamin E are acceptable only as part of a standard multivitamin formulation. - Previous surgery, including plastic surgery, lifting threads, tissue grafting, or tissue augmentation with permanent implants, silicone, tattoo affecting the treatment area, or any procedure, at the discretion of the Investigator, would interfere with the outcome of the study. - Any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion - Other condition preventing the subject from entering the study in the Investigator's opinion - Study site personnel, close relatives of the study site personnel (e.g., parents, children, siblings, or spouse), or employees and close relatives of employees at the Sponsor company. - Participation in any interventional clinical study within 30 days of screening. |
Country | Name | City | State |
---|---|---|---|
United States | Lorenc Aesthetic Plastic Surgery Center | New York | New York |
United States | Somenek + Pittman MD: Advanced Plastic Surgery | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Galderma R&D |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in skin hydration from baseline | Corneometer (Courage + Khazaka, Germany) measurements will be taken in triplicate to assess skin hydration. The Corneometer measures in Corneometer units from 0 (no water at all) - 120 (on water).The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth. An increase in scores indicates an improvement. | Baseline, Week 4, Week 8, Week 16 or Week 20 | |
Primary | Change in skin radiance from baseline | Glossymeter (Courage + Khazaka, Germany) measurements will be taken to assess skin radiance. The results will be expressed in Glossymeter units. The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth. An increase in scores indicates an improvement. | Baseline, Week 4, Week 8, Week 16 or Week 20 | |
Primary | Change in skin elasticity from baseline | Cutometer (Courage + Khazaka, Germany) measurements will be taken to assess skin elasticity. The Cutometer measures skin elasticity in mm penetration depth per unit of time. The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth. An increase in scores indicates an improvement. | Baseline, Week 4, Week 8, Week 16 or Week 20 | |
Primary | Change in skin thickness from baseline | DermaLab® Ultrasound (Cortex Technology, Denmark) measurements will be taken in triplicate to assess skin thickness in µm. The locations of measurement will be at (1) the zygoma area in the Restylane-treated region using a ruler starting from the corner of the eye and (2) 2-3 cm laterally from the end of the earlobe in the Sculptra-injected region using a ruler starting from the end of the earlobe to the corner of the mouth. An increase in scores indicates an improvement. | Baseline, Week 4, Week 8, Week 16 or Week 20 | |
Secondary | Subject Treatment Satisfaction | Subjects will be asked about their perception and satisfaction with the study treatments using a self-assessment questionnaire at each visit after Baseline. Questionnaires will be tabulated; and the frequency and percentage of all response options will be reported for each question and time point. Favorable responses (i.e., strongly agree and agree, yes), neutral responses (i.e., neither agree nor disagree, no difference), and unfavorable responses (i.e., strongly disagree and disagree, no) will be tabulated and reported as appropriate. | Week 4, Week 8, Week 16 or Week 20 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Terminated |
NCT03316105 -
Effect of T6 Dermatome Electrical Stimulation on Gastroduodenal Motility in Healthy Volunteers
|
N/A | |
Completed |
NCT03700736 -
The Healthy Moms Study: Comparison of a Post-Partum Weight Loss Intervention Delivered Via Facebook or In-Person Groups
|
N/A | |
Active, not recruiting |
NCT04353726 -
Knowledge-based Dietary Weight Management.
|
N/A | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03377244 -
Healthy Body Healthy Souls in the Marshallese Population
|
N/A | |
Completed |
NCT02877004 -
LLLT for Reducing Waste Circumference and Weight
|
N/A | |
Active, not recruiting |
NCT04327141 -
Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women
|
N/A | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Recruiting |
NCT05942326 -
Sleep Goal-focused Online Access to Lifestyle Support
|
N/A | |
Completed |
NCT00535600 -
Effects of Bariatric Surgery on Insulin
|
||
Not yet recruiting |
NCT03601273 -
Bariatric Embolization Trial for the Obese Nonsurgical
|
Phase 1 | |
Active, not recruiting |
NCT04357119 -
Common Limb Length in One-anastomosis Gastric Bypass
|
N/A | |
Completed |
NCT02948517 -
Time Restricted Feeding for Weight Loss and Cardio-protection
|
N/A | |
Completed |
NCT03210207 -
Gastric Plication in Mexican Patients
|
N/A | |
Completed |
NCT03139760 -
POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability
|
N/A | |
Completed |
NCT02945410 -
Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity
|
N/A | |
Recruiting |
NCT02559479 -
A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes
|
N/A |